서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Publisher

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 40 of 44

Issue DateTitle / Author(s) / CitationFileAltmetrics
2000-03
Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis

Kim, SJ; Im, YH; Markowitz, SD; Bang, YJ

Cytokine and Growth Factor Reviews, Vol.11 No.1-2, pp.159-168

DOI
2008
Overexpression of A-kinase anchoring protein 12A activates sterol regulatory element binding protein-2 and enhances cholesterol efflux in hepatic cells

Choi, Moon-Chang; Lee, Yang-Ui; Kim, Sung-Hak; Lee, Ju-Hee; Park, Jung-Hyun; Streb, Jeffrey W.; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Jong, Hyun-Soon; Bang, Yung-Jue

International Journal of Biochemistry and Cell Biology, Vol.40 No.11, pp.2534-2543

DOI
2008
DNA methyltransferase 3B acts as a co-repressor of the human polycomb protein hPc2 to repress fibroblast growth factor receptor 3 transcription

Kim, Sung-Hak; Park, Jinah; Choi, Moon-Chang; Park, Jung-Hyun; Kim, Hwang-Phill; Lee, Ju-Hee; Oh, Do-Youn; Im, Seock-Ah; Bang, Yung-Jue; Kim, Tae-You

International Journal of Biochemistry and Cell Biology, Vol.40 No.11, pp.2462-2471

DOI
2011-03
The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation
DOI
2012-11
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer
DOI
2013-05
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
DOI
2014-03
VEGF-binding aptides and the inhibition of choroidal and retinal neovascularization
DOI
2014-03
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy
DOI
2014-09
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
DOI
2016-01
Observer variability in RECIST-based tumour burden measurements: A meta-analysis

Yoon, Soon Ho; Kim, Kyung Won; Goo, Jin Mo; Kim, Dong-Wan; Hahn, Seo Kyung

European Journal of Cancer, Vol.53, pp.5-15

DOI
2016-09
A high affinity kidney targeting by chitobionic acid-conjugated polysorbitol gene transporter alleviates unilateral ureteral obstruction in rats
DOI
2016-12
Nanoparticle-protein complexes mimicking corona formation in ocular environment
DOI
2017-01
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
DOI
2017-03
In vivo visualization of endogenous miR-21 using hyaluronic acid-coated graphene oxide for targeted cancer therapy
view fileDOI
2017-05
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
DOI
2017-09
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria
DOI
2017-11
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
DOI
2018-04
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
DOI
2018-09
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies
DOI
2018-11
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
DOI
2018-11
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3
DOI
2018-11
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
DOI
2019-02
Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases
DOI
2019-02
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
DOI
2019-03
A terpolymeric hydrogel of hyaluronate-hydroxyethyl acrylate-gelatin methacryloyl with tunable properties as biomaterial
DOI
2019-05
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
view fileDOI
2019-10
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
DOI
2019-12
Prognostic plasma protein panel for A beta deposition in the brain in Alzheimer's disease
DOI
2020-01
Non-invasive in vivo imaging of caspase-1 activation enables rapid and spatiotemporal detection of acute and chronic inflammatory disorders
DOI
2020-06
Mesenchymal stem cell-derived magnetic extracellular nanovesicles for targeting and treatment of ischemic stroke
view fileDOI
2020-09
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
DOI
2021-01
Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm
DOI
2021-07
Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report
DOI
2022-01
Voltage-gated calcium channels contribute to spontaneous glutamate release directly via nanodomain coupling or indirectly via calmodulin

Lee, Byoung Ju; Yang, Che Ho; Lee, Seung Yeon; Lee, Suk-Ho; Kim, Yujin; Ho, Won-Kyung

Progress in Neurobiology, Vol.208, p. 102182

DOI
2022-07
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability–high/mismatch repair–deficient advanced solid tumours: Results from the KEYNOTE-158 study
DOI
2022-08
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study
DOI
2022-09
Ultrasensitive probeless capacitive biosensor for amyloid beta (Aβ1-42) detection in human plasma using interdigitated electrodes
DOI
2022-09
Exposure to several polychlorinated biphenyls (PCBs) is associated with chronic kidney disease among general adults: Korean National Environmental Health Survey (KoNEHS) 2015-2017
DOI
2022-09
Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study
DOI
2022-10
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
DOI
1 2